Two-year trends from the LANDMARC study: A 3-year, pan-India, prospective, longitudinal study on the management and real-world outcome in patients with type 2 diabetes mellitus

被引:0
|
作者
Das, Ashok K. [1 ]
Kalra, Sanjay [2 ]
Joshi, Shashank [3 ]
Mithal, Ambrish [4 ]
Kumar, K. M. Prasanna [5 ]
Unnikrishnan, Ambika G. [6 ]
Thacker, Hemant [7 ]
Sethi, Bipin [8 ]
Chowdhury, Subhankar [9 ]
Sugumaran, Amarnath [10 ]
Mohanasundaram, Senthilnathan [10 ]
Menon, Shalini K. [10 ]
Salvi, Vaibhav [10 ]
Chodankar, Deepa [10 ]
Thaker, Saket [10 ]
Trivedi, Chirag [10 ]
Wangnoo, Subhash K. [11 ]
Zargar, Abdul H. [12 ]
Rais, Nadeem [13 ]
机构
[1] Pondicherry Inst Med Sci, Pondicherry, India
[2] Bharti Hosp, Karnal, India
[3] Lilavati Hosp, Mumbai, India
[4] Medanta The Med, Gurgaon, India
[5] Ctr Diabet & Endocrine Care, Bengaluru, India
[6] Chellaram Diabet Inst, Pune, India
[7] Bhatia Hosp, Mumbai, India
[8] Care Hosp, Hyderabad, India
[9] IPGME & R & SSKM Hosp, Kolkata, India
[10] Sanofi, Sect 12,Kunjpura Rd, Mumbai 132001, Haryana, India
[11] Apollo Hosp Educ & Res Fdn, New Delhi, India
[12] Ctr Diabet & Endocrine Care, Srinagar, India
[13] Chowpatti Med Ctr, Mumbai, India
关键词
cardiovascular diseases; diabetes complications; diabetic nephropathies; glycaemic control; OBESITY;
D O I
10.1002/edm2.404
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: There are limited data on the real world management of diabetes in the Indian population. In this 2-year analysis of the LANDMARC study, the management of type 2 diabetes mellitus (T2DM) and related complications were assessed.Method: This multicenter, observational, prospective study included adults aged >= 25 to <= 60 years diagnosed with T2DM (duration >= 2 years at enrollment) and controlled/ uncontrolled on >= 2 anti-diabetic agents. This interim analysis at 2 years reports the status of glycaemic control, diabetic complications, cardiovascular (CV) risks and therapy, pan India including metropolitan and non-metropolitan cities.Results: Of the 6234 evaluable patients, 5318 patients completed 2 years in the study. Microvascular complications were observed in 17.6% of patients (1096/6234); macro vascular complications were observed in 3.1% of patients (195/6234). Higher number of microvascular complications were noted in patients from non-metropolitan than in metropolitan cities (p < .0001). In 2 years, an improvement of 0.6% from baseline (8.1%) in mean glycated haemoglobin (HbA1c) was noted; 20.8% of patients met optimum glycaemic control (HbA1c < 7%). Hypertension (2679/3438, 77.9%) and dyslipidaemia (1776/3438, 51.7%) were the predominant CV risk factors in 2 years. The number of patients taking oral anti-diabetic drugs in combination with insulin increased in 2 years (baseline: 1498/6234 [24.0%] vs. 2 years: 1917/5763 [33.3%]). While biguanides and sulfonylureas were the most commonly prescribed, there was an evident increase in the use of dipeptidyl peptidase-IV inhibitors (baseline: 3049/6234, 48.9% vs. 2 years: 3526/5763, 61.2%).Conclusion: This longitudinal study represents the control of T2DM, its management and development of complications in Indian population.
引用
收藏
页数:11
相关论文
共 33 条
  • [21] A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study
    Elhayany, A.
    Lustman, A.
    Abel, R.
    Attal-Singer, J.
    Vinker, S.
    DIABETES OBESITY & METABOLISM, 2010, 12 (03) : 204 - 209
  • [22] Does 10-Year Atherosclerotic Cardiovascular Disease Risk Predict Incident Diabetic Nephropathy and Retinopathy in Patients with Type 2 Diabetes Mellitus? Results from Two Prospective Cohort Studies in Southern China
    Chen, Jiaheng
    Li, Yu Ting
    Niu, Zimin
    He, Zhanpeng
    Xie, Yao Jie
    Hernandez, Jose
    Huang, Wenyong
    Wang, Harry H. X.
    Guangzhou Diabetic Eye Study Group
    DIABETES & METABOLISM JOURNAL, 2025, 49 (02) : 298 - 310
  • [23] Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study
    Natalia Duque
    Esther Artime
    Irene Romera
    Jeremie Lebrec
    Silvia Díaz
    Miriam Rubio
    Antoni Sicras-Mainar
    Enrique Carretero-Anibarro
    Xavier Mundet
    Juan J. Gorgojo-Martínez
    Jesús Reviriego
    Advances in Therapy, 2021, 38 : 3857 - 3871
  • [24] 1-year weight change after diabetes diagnosis and long-term incidence and sustainability of remission of type 2 diabetes in real-world settings in Hong Kong: An observational cohort study
    Wu, Hongjiang
    Yang, Aimin
    Lau, Eric S. H.
    Zhang, Xinge
    Fan, Baoqi
    Ma, Ronald C. W.
    Kong, Alice P. S.
    Chow, Elaine
    So, Wing-Yee
    Chan, Juliana C. N.
    Luk, Andrea O. Y.
    PLOS MEDICINE, 2024, 21 (01)
  • [25] Initiating or switching to insulin degludec/insulin aspart in a real-world population of adults with type 2 diabetes in Australia: results from a prospective, non-interventional study
    Fulcher, Gregory R.
    Cohen, Neale D.
    Davies, Katherine
    d'Emden, Michael
    Glastras, Sarah J.
    Mah, Peak M.
    McCallum, Roland W.
    Moses, Robert
    Thong, Ken Y.
    Roberts, Anthony
    INTERNAL MEDICINE JOURNAL, 2024, 54 (10) : 1626 - 1633
  • [26] Secular Trends in Dietary Intake over a 20-Year Period in People with Type 2 Diabetes in Japan: A Comparative Study of Two Nationwide Registries; Japan Diabetes Complications Study (JDCS) and Japan Diabetes Clinical Data Management Study (JDDM)
    Takeuchi, Mizuki
    Horikawa, Chika
    Hatta, Mariko
    Takeda, Yasunaga
    Nedachi, Rina
    Ikeda, Izumi
    Morikawa, Sakiko
    Kato, Noriko
    Yokoyama, Hiroki
    Aida, Rei
    Tanaka, Shiro
    Kamada, Chiemi
    Yoshimura, Yukio
    Saito, Toshiko
    Fujihara, Kazuya
    Araki, Atsushi
    Sone, Hirohito
    NUTRIENTS, 2021, 13 (10)
  • [27] Real-World Adequacy of Glycaemic Control in Treatment-Naive Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study
    Tsimihodimos, Vasilis
    Bargiota, Alexandra
    Pagkalos, Emmanouil M.
    Manes, Christos
    Papas, Aggelos
    Karamousouli, Eugenia
    Voss, Bernd
    Elisaf, Moses S.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2020, 128 (04) : 224 - 230
  • [28] Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study
    Yabe, Daisuke
    Yamamoto, Fumiko
    Lund, Soren S.
    Okamura, Tomoo
    Kadowaki, Takashi
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (10) : 1303 - 1313
  • [29] Association of age at diagnosis of type 2 diabetes mellitus with the risks of the morbidity of cardiovascular disease, cancer and all-cause mortality: Evidence from a real-world study with a large population-based cohort study
    Li, Yuhao
    Luo, Jinbin
    Bao, Kaifang
    Wei, Qiaohui
    Wang, Xiaohong
    Chen, Jieping
    Zhang, Tao
    Wang, Fengying
    Zhu, Yimin
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 217
  • [30] Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study
    Abusnana, Salah
    Al Awadi, Fatheya
    Aly, Hazem
    Bashier, Alaaeldin
    Dhanwal, Dinesh Kumar
    Halasa, Tariq
    Jallo, Mahir
    Medina, Johan
    Singhal, Sagar
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 196